Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study

• Autori principali: A. David Burden (Autore), Robert Bissonnette (Autore), Alexander A. Navarini (Autore), Masamoto Murakami (Autore), Akimichi Morita (Autore), Thomas Haeufel (Autore), Binqi Ye (Autore), Frank Baehner (Autore), Tadashi Terui (Autore)
• Natura: Libro
• Pubblicazione: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Introduction We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP). Methods This phase IIb trial comprised a loading dose period to week (W) 4, then maintenance dosing to W52. Patients were randomised 2:1:1:1:2 to...